Quantum BioPharma (QNTM) 6-K 12 Nov 24 2024 Q3 Condensed consolidated interim financial statements Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2024
Cover [Abstract]
Entity Registrant Name	QUANTUM BIOPHARMA LTD.
Entity Central Index Key	0001771885
Document Type	6-K
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Entity Ex Transition Period	false
Entity File Number	001-39152
Entity Address Address Line 1	55 University Ave.
Entity Address Address Line 2	Suite 1003
Entity Address City Or Town	Toronto
Entity Address State Or Province	ON
Entity Address Country	CA
Entity Address Postal Zip Code	M5J2H7

CONDENSED CONSOLIDATED INTERIM

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 3,120,226	$ 2,757,040
Other receivables	104,204	228,764
Prepaid expenses and deposits	150,325	155,413
Short-term investments	3,485,424	756,100
Finance receivables, net	6,983,513	7,187,988
Current assets	13,843,692	11,085,305
Non-current assets
Equipment, net	64,909	87,583
Long-term investments	5,926	6,049
Right-of-use asset, net	72,374	32,838
Finance receivables, net	0	907,366
Intangible assets, net	5,039,901	5,355,687
Total assets	19,026,802	17,474,828
Current liabilities
Trade and other payables	3,307,936	4,195,029
Lease obligations	72,475	38,650
Warrants liability	75	31,338
Notes payable	300,549	300,549
Total liabilities	3,681,035	4,565,566
SHAREHOLDERS' EQUITY
Warrants	1,997,759	2,723,356
Contributed surplus	31,128,922	30,225,741
Foreign exchange translation reserve	833,061	417,341
Accumulated deficit	(166,750,621)	(157,908,160)
Equity attributable to shareholders of the Company	16,290,058	13,236,763
Non-controlling interests	(944,291)	(327,501)
Shareholders equity	15,345,767	12,909,262
Total liabilities and shareholders' equity	19,026,802	17,474,828
Class B Common Shares [Member]
SHAREHOLDERS' EQUITY
Share capital	148,929,236	137,626,863
Shareholders equity	148,929,236	137,626,863
Class A Common Shares [Member]
SHAREHOLDERS' EQUITY
Share capital	151,701	151,622
Shareholders equity	$ 151,701	$ 151,622

CONDENSED CONSOLIDATED INTERI_2

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Expenses
General and administrative	$ 3,250,030	$ 3,071,889	$ 7,479,525	$ 7,659,424
External research and development fees	744,802	32,985	1,803,048	3,889,139
Share-based payments	65,424	126,163	234,691	3,736,091
Depreciation and amortization	120,814	146,810	377,768	2,384,099
Impairment loss	0	0	0	4,319,619
Total operating expenses	4,181,070	3,311,877	9,895,032	21,988,372
Loss from operations	(4,181,070)	(3,311,877)	(9,895,032)	(21,988,372)
Interest income	(163,868)	(174,068)	(440,816)	(632,572)
Finance expense (income), net	(10,371)	380	(31,142)	(287)
(Gain) loss on settlement of debt	(12,320)	0	5,156	0
Gain on measurement of financial liability	0	(2,012,093)	0	(4,939,015)
(Gain) loss on change in fair value of derivative liability	74	8,032	(31,263)	(113,211)
(Gain) loss on changes in fair value of investments	0	2,168	0	(275,161)
Net loss from operations	(4,015,327)	(1,131,200)	(9,459,251)	(16,579,022)
Other comprehensive loss
Exchange gain on translation of foreign operations	749,564	267,348	415,720	49,859
Comprehensive loss	(3,265,763)	(863,852)	(9,043,531)	(16,529,163)
Net loss attributable to:
Equity owners of the Company	(3,827,170)	(1,059,838)	(8,842,461)	(16,507,660)
Non-controlling interests	(188,157)	(71,362)	(616,790)	(71,362)
Net loss attributable	$ (4,015,327)	$ (1,131,200)	$ (9,459,251)	$ (16,579,022)
Net loss per share
Basic and diluted	$ (4.37)	$ (1.88)	$ (11.06)	$ (27.17)
Weighted average number of shares outstanding - basic and diluted	917,848	602,962	855,294	610,195

CONDENSED CONSOLIDATED INTERI_3

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)	Total	Retained Earnings (Accumulated Deficit)	Class A Shares [Member]	Class B Shares [Member]	Warrants Stock Share [Member]	Contributed Surplus [Member]	Foreign Exchange Translation Reserve [Member]	Noncontrolling Interest [Member]
Balance, shares at Dec. 31, 2022			2	592,372	99,725
Balance, amount at Dec. 31, 2022	$ 30,542,220	$ (144,164,265)	$ 151,588	$ 143,258,972	$ 2,142,400	$ 28,500,924	$ 652,601	$ 0
Statement [Line Items]
Initial recognition of non-controlling interests	(65,050)	(40,583)	0	$ 0	0	0	0	(24,467)
Share repurchase shares [note 11]				(29,303)
Share repurchase amount [note 11]	(2,957,816)	4,207,540	0	$ (7,165,356)	0	0	0	0
Share-based payments shares [note 12]				280
Share-based payments amount [note 12]	$ 2,406,048	0	0	$ 16,000	0	2,383,745	0	6,303
Share options exercised shares [note 11]	323			323
Share options exercised amount[note 11]	$ 20,247	0	0	$ 33,247	0	(13,000)	0	0
PSUs converted to shares [note 11,12]				41,848
PSUs converted to shares amount [note 11,12]	0	0	0	$ 1,464,000	$ 0	(1,464,000)	0	0
Warrants issued shares [note 11]					61,154
Warrants issued amount [note 11]	1,330,043	0	0	0	$ 1,330,043	0	0	0
Warrants expired shares [note 11					(2,047)
Warrants expired amount [note 11	0	0	0	0	$ (791,807)	791,807	0	0
Comprehensive loss for the period	(16,529,163)	(16,507,660)	$ 0	$ 0	$ 0		49,859	(71,362)
Balance, shares at Sep. 30, 2023			2	605,520	158,832
Balance, amount at Sep. 30, 2023	14,746,529	(156,504,968)	$ 151,588	$ 137,606,863	$ 2,680,636	30,199,476	702,460	(89,526)
Balance, shares at Dec. 31, 2023			2	137,626,863	2,723,356
Balance, amount at Dec. 31, 2023	12,909,262	(157,908,160)	$ 151,622	$ 605,796	$ 158,831	30,225,741	417,341	(327,501)
Statement [Line Items]
Share-based payments amount [note 12]	$ 234,691	0	0	0	$ 0	234,691	0	0
Share options exercised shares [note 11]	248,160
Warrants expired shares [note 11					(20,769)
Warrants expired amount [note 11	$ 0	0	0	0	$ (286,189)	286,189	0	0
Comprehensive loss for the period	(9,043,531)	(8,842,461)	$ 0	$ 0	0	0	415,720	(616,790)
Shares issued shares [note 11]			10	956,935
Shares issued amount [note 11]	9,185,152	0	$ 79	$ 9,185,073	0	0	0	0
Shares for debt shares [note 11,12]				292,477
Shares for debt amount [note 11,12]	1,983,728	0	0	$ 1,983,728	$ 0	0	0	0
Warrants cancelled shares [note 11]					(7,692)
Warrants cancelled amount [note 11]	0	0	0	$ 0	$ (439,408)	439,408	0	0
Exercise of options shares [note 11,12]				1,446
Exercise of options amount [note 11,12]	76,465	0	0	$ 102,563	0	(26,098)	0	0
RSUs converted to shares [note 11,12]				7,500
RSUs converted to shares amount [note 11,12]	0	0	$ 0	$ 31,009	$ 0	(31,009)	0	0
Balance, shares at Sep. 30, 2024			12	1,864,154	130,370
Balance, amount at Sep. 30, 2024	$ 15,345,767	$ (166,750,621)	$ 151,701	$ 148,929,236	$ 1,997,759	$ 31,128,922	$ 833,061	$ (944,291)

CONDENSED CONSOLIDATED INTERI_4

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net loss from operations	$ (9,459,251)	$ (16,579,022)
Add (deduct) items not affecting cash
Depreciation and amortization	377,768	2,384,099
Interest expense	31,142	21,201
Share-based payments	234,691	3,736,091
Change in fair value of investments	0	(275,161)
Change in fair value of derivative liability	(31,263)	(113,211)
Unrealized foreign exchange (gain) loss	(414,491)	0
Loss on settlement of debt	(5,156)	0
Gain on measurement of financial liability	0	(4,939,015)
Impairment loss	0	4,319,619
Changes in non-cash working capital balances
Finance receivables	(1,111,841)	(634,080)
Other receivables	124,560	174,139
Prepaid expenses and deposits	5,088	123,771
Note receivable	0	(219,082)
Trade and other payables	1,145,060	1,474,719
Cash used in operating activities	(6,040,717)	(9,975,610)
Investing activities
Redemption of investments	738,000	0
Purchase of investments	(3,485,424)	(744,500)
Net cash upon control of subsidiary	0	31,783
Proceeds from sale of investments	0	443,138
Cash (used in) provided by investing activities	(2,747,424)	(269,579)
Financing activities
Shares repurchase	0	(2,957,816)
Proceeds from issuance of shares, net	9,185,152	0
Proceeds from loan payable	0	0
Payment of lease obligation	(33,825)	(163,803)
Share options exercised	0	20,247
Cash (used in) provided by financing activities	9,151,327	(3,101,372)
Net increase (decrease)	363,186	(13,346,561)
Cash and cash equivalents, beginning of the period	2,757,040	16,980,472
Cash and cash equivalents, end of the period	3,120,226	3,633,911
Non-cash transactions
Shares issued for debt	1,983,728	0
Exercise of options - shares issued for services	102,563	0
Recognition of right of use asset	78,949	0
RSUs converted to shares	$ 31,009	$ 0

Nature of business

Nature of business	9 Months Ended
	Sep. 30, 2024
Nature of business
Nature of business	1. Nature of business Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (“Quantum” or the “Company”) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum is also focused on the research and development of a treatment for alcohol misuse for application in hospitals and other medical practices. Quantum maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential property. The Company’s registered office is located at 55 University Avenue, Suite 1003, Toronto, Ontario, M5J 2H7. On August 15, 2024, the Company consolidated its Class A Multiple Voting Shares and Class B Subordinate Voting Shares (each as defined hereinafter) on a 65:1 basis and changed its name to "Quantum BioPharma Ltd." with a new trading symbol "QNTM" on both NASDAQ and CSE. On July 31, 2023, the Company entered into an exclusive intellectual property license agreement (the “License Agreement”) with Celly Nutrition Corp. (“Celly”). The License Agreement provides Celly access to proprietary information for the purposes of consumer product development and marketing. The License Agreement grants Celly the rights to a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. The License Agreement also grants Celly rights to certain trademarks. In exchange, Quantum received 200,000,000 common shares in the capital of Celly following a 2:1 share-split. The Company also received an anti-dilution Warrant Certificate that entitles Quantum to purchase up to 25% of the common shares deemed outstanding less the 200,000,000 common shares issued under the License Agreement and from time to time as a result of any partial exercise under the anti-dilution Warrant Certificate. Quantum is also entitled to certain license fees and royalties under the License Agreement. Through the License Agreement, Quantum acquired 34.66% of Celly. On July 31, 2023, the Company and Celly entered into a loan agreement for gross proceeds of C$1,000,000. The loan was funded on August 1, 2023, and accrues interest at a rate of 10% per annum. Interest is payable annually and the loan matures on July 31, 2026. In November 2023, through the Plan of Arrangement the Company distributed 703,270 of its 3,076,923 shares of Celly to its shareholders. The condensed consolidated interim financial statements incorporate the assets and liabilities of Celly as of September 30, 2024, and the results of operations and cash flows for the three and nine months ended September 30, 2024 [Note 2(c)]. As of September 30, 2024, the Company had a 24.15% (December 31, 2023 - 26.15%) ownership interest in Celly through common shares held in Celly. Going concern The condensed consolidated interim financial statements of the Company for the three and nine months ended September 30, 2024, and 2023, have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of operations. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that would be necessary should the Company be unable to continue as a going concern. Such adjustments could be material. The Company is in the preliminary stages of its planned operations and has not yet determined whether its processes and business plans are economically viable. The continued operations of the Company and the recoverability of amounts shown for intangible assets are dependent upon the ability of the Company to obtain sufficient financing to complete the research and development program of Lucid-MS. As well as fund the research and development of a treatment for alcohol misuse for application in hospitals and other medical practices. As at September 30, 2024, the Company had an accumulated deficit of $166,750,621 (December 31, 2023 - $157,908,160) and working capital of $10,162,657 (December 31, 2023 - $6,519,739), and incurred net loss of $9,459,251 (2023 - $16,579,022) for the nine months ended September 30, 2024. Whether, and when, the Company can attain profitability and positive cash flows from operations is subject to material uncertainty. The application of the going concern assumption is dependent upon the Company’s ability to generate future profitable operations and obtain necessary financing to do so. The Company will need to raise additional capital to fund its planned operations and meet its obligations. While the Company has been successful in obtaining financing to date and believes it will be able to obtain sufficient funds in the future and ultimately achieve profitability and positive cash flows from operations, there can be no assurance that the Company will achieve profitability and be able to do so on terms favourable for the Company. The above events and conditions indicate there is a material uncertainty that casts substantial doubt about the Company’s ability to continue as a going concern. Subsidiaries These condensed consolidated interim financial statements are comprised of the financial results of the Company and its subsidiaries, which are the entities over which the Company has control. An investor controls an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and can affect those returns through its power over the investee. The Company has the following subsidiaries: Ownership percentage as at Ownership percentage as at Entity Name Country September 30, 2024 December 31, 2023 % % FSD Biosciences Inc. USA 100.00 100.00 Prismic Pharmaceuticals Inc. USA 100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 FSD Pharma Australia Pty Ltd Australia 100.00 100.00 Celly Nutrition Corp. Canada 24.15 26.15 Huge Biopharma Australia Pty Ltd Australia 100.00 - Non-controlling interests (“NCI”) represent ownership interests in consolidated subsidiaries by parties that are not shareholders of the Company. They are shown as a component of total equity in the condensed consolidated interim statements of financial position, and the share of income (loss) attributable to non-controlling interests is shown as a component of net income (loss) in the condensed consolidated interim statements of loss and comprehensive loss. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 30, 2024
Basis of presentation
Basis of presentation	2. Basis of presentation [a] Statement of compliance These condensed consolidated interim financial statements (“financial statements”) were prepared using the same accounting policies and methods as those used in the Company’s audited consolidated financial statements for the year ended December 31, 2023. These financial statements have been prepared in compliance with IAS 34 – Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) have been omitted or condensed. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2023. These financial statements were approved and authorized for issuance by the Board of Directors (the “Board”) of the Company on November 5, 2024. [b] Functional currency and presentation currency The financial statements of each company within the consolidated group are measured using their functional currency, which is the currency of the primary economic environment in which an entity operates. These condensed consolidated interim financial statements are presented in United States dollars ("USD"), which is the Company’s functional and presentation currency for all periods presented. The Company’s functional currency is the United States dollar and the functional currencies of its subsidiaries are as follows: FSD Biosciences Inc. United States Dollar Prismic Pharmaceuticals Inc. United States Dollar FV Pharma Inc. Canadian Dollar Lucid Psycheceuticals Inc. Canadian Dollar FSD Strategic Investments Inc. Canadian Dollar FSD Pharma Australia Pty Ltd Australian Dollar Celly Nutrition Corp. Canadian Dollar Huge Biopharma Australia Pty Ltd Australian Dollar [c] Use of estimates and judgments The preparation of these financial statements in conformity with IFRS requires management to make estimates, judgements and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, consistent with those disclosed in the audited consolidated financial statements for the year ended December 31, 2023, and described in these financial statements. Actual results could differ from these estimates. Estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Disclosure of interests in other entities To assess the investment in Celly, judgment was required to determine if the Company has significant influence or control of Celly. The Company considered the relevant guidance in IFRS 10 – Consolidated Financial Statements, IAS 24 – Related Party Disclosures and IAS – 28 Investments in Associates and Joint Ventures. Judgment is applied in determining when the Company controls an investment even if the Company holds less than a majority of the investee’s voting rights (the existence of de facto control). The Company concluded it has control of Celly even though the Company only held 24.15% of the voting rights as of September 30, 2024 (December 31, 2023 – 26.15%). The Company concluded it has control of Celly as the Company, together with persons or entities considered to be de facto agents of the Company, held a combined 63.65% (December 31, 2023 - 52.05%) of the voting rights of Celly. In addition, key management personnel of the Company hold three of the four board of director positions of Celly. The assessment of control is performed on a continuous basis. The Company determined that it obtained control of Celly on July 31, 2023, and control was maintained from July 31, 2023, through September 30, 2024. Celly is significantly dependent on the Company as a result of the License Agreement and the loan. The NCI component of Celly is included as a separate component in equity (Note 13). New standards, amendments and interpretations not yet adopted by the Company IFRS 16 – Leases (“IFRS 16”) In September 2022, the IASB issued amendments to IFRS 16, Leases, which add to requirements explaining how a company accounts for a sale and leaseback after the date of the transaction. The amendments are effective for annual reporting periods beginning on or after January 1, 2024. Earlier application is permitted. The amendment did not have a material impact on the financial statements. All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the financial statements.

Other receivables

Other receivables	9 Months Ended
	Sep. 30, 2024
Other receivables
Other receivables	3. Other receivables The Company’s other receivables are comprised of the following: September 30, 2024 December 31, 2023 $ $ Sales tax recoverable 70,478 209,550 Interest receivable 28,852 15,511 Other receivables 4,874 3,703 104,204 228,764

Prepaid expenses and deposits

Prepaid expenses and deposits	9 Months Ended
	Sep. 30, 2024
Prepaid expenses and deposits
Prepaid expenses and deposits	4. Prepaid expenses and deposits The Company’s prepaid expenses and deposits include the following: September 30, 2024 December 31, 2023 $ $ Research and development 46,809 30,705 Insurance 58,708 60,999 Other prepaids and deposits 44,808 63,709 150,325 155,413

Finance receivables

Finance receivables	9 Months Ended
	Sep. 30, 2024
Finance receivables
Finance receivables	5. Finance receivables Finance receivables consist of secured loan receivables measured at amortized cost, net of allowance for expected credit losses. Finance receivables as at September 30, 2024 are as follows: $ Balance – January 1, 2024 8,095,354 Add: Additions 2,452,033 Add: Interest income 397,939 Less: Interest payments (367,346 ) Less: Principal payments (3,390,767 ) Effects of foreign exchange (203,700 ) Balance – September 30, 2024 6,983,513 Current 6,983,513 Non-current - Balance – September 30, 2024 6,983,513 Allowances for expected credit losses as at September 30, 2024, were $nil (December 31, 2023 - $nil). Finance receivables earn fees at fixed rates and have an average term to maturity of two years from the date of issuance. The loans are secured by residential property with a first or second collateral mortgage on the secured property, except for the loan issued to a related party. Loans are issued up to 55% of the initial appraised value of the secured property at the time of issuance. Finance receivables include the following as at September 30, 2024: $ Minimum payments receivable 6,647,037 Unearned income 336,476 Net investment 6,983,513 Allowance for credit losses — Finance receivables, net 6,983,513 As at September 30, 2024, all loans were classified at amortized cost.

Investments

Investments	9 Months Ended
	Sep. 30, 2024
Investments
Investments	6. Investments The following tables outline changes in investments during the periods: Entity Instrument Note Balance at December 31, 2023 Additions Redemptions Effects of foreign exchange Balance at September 30 , 2024 $ $ $ $ A2ZCryptoCap Inc. Shares (i) 6,049 — — (123 ) 5,926 Royal Bank of Canada GIC (ii) 756,100 — (738,000 ) (18,100 ) — Royal Bank of Canada GIC (iii) — 2,985,424 — — 2,985,424 Bank of Montreal GIC (iv) — 500,000 — — 500,000 762,149 3,485,424 (738,000 ) (18,223 ) 3,491,350 Current 3,485,424 Non-Current 5,926 3,491,350 (i) A2ZCryptoCap Inc. (“A2Z”) On June 23, 2022, the Company acquired 80,000 shares of A2Z for C$0.10 per share. As at September 30, 2024, the fair value of the shares was determined based on the quoted market price of the shares of C$0.10 per share (December 31, 2023 – C$0.10). The shares have been classified as level 1 within the fair value hierarchy – quoted market price. (ii) On August 9, 2023, the Company purchased a Guaranteed Investment Certificate (“GIC”) in the amount of $744,500 from Royal Bank of Canada (“RBC”) with a maturity date of August 9, 2024. The GIC pays variable interest based on RBC’s Prime Interest Rate minus 2.00%. The GIC has been classified as level 2 – valuation technique with observable market inputs. During the nine months ended September 30, 2024, the Company redeemed the full amount for gross proceeds of $738,000. The balance outstanding as at September 30, 2024 is $nil. iii) During the nine months ended September 30, 2024, the Company purchased four GICs for a total amount of $2,985,424 from RBC with maturity dates ranging from February 14, 2025, to September 12, 2025. The GICs pay variable interest ranging from 4.00% to 4.45% per annum. As of September 30, 2024, the total balance outstanding, including interest accrued of $28,852 is $3,014,276. The GICs have been classified as level 2 – valuation technique with observable market inputs. iv) During the nine months ended September 30, 2024, the Company purchased a GIC in the amount of $500,000 from Bank of Montreal (BMO) with a maturity date of October 11, 2024. The GIC pays variable interest of 4.50% per annum. As of September 30, 2024, the total balance outstanding, including interest accrued of $1,171 is $501,171. The GIC has been classified as level 2 – valuation technique with observable market inputs.

Intangible assets

Intangible assets	9 Months Ended
	Sep. 30, 2024
Intangible assets
Intangible assets	7. Intangible assets Intangible assets as at September 30, 2024 are as follows: Cost Innovet Prismic Lucid Total As at December 31, 2022 750,000 19,201,493 6,314,571 26,266,064 Impairment (750,000 ) (19,201,493 ) — (19,951,493 ) As at December 31, 2023 and September 30, 2024 — — 6,314,571 6,314,571 Accumulated amortization As at December 31, 2022 229,933 13,457,622 538,220 14,225,775 Amortization 39,971 1,904,348 420,664 2,364,983 Impairment (269,904 ) (15,361,970 ) — (15,631,874 ) As at December 31, 2023 — — 958,884 958,884 Amortization — — 315,786 315,786 As at September 30, 2024 — — 1,274,670 1,274,670 Net book value As at December 31, 2023 — — 5,355,687 5,355,687 As at September 30, 2024 — — 5,039,901 5,039,901 The Company’s intangible asset for Lucid represents the license agreement with the University Health Network giving the Company world-wide exclusive rights to the Lucid-MS compound and related patents.

Trade and other payables

Trade and other payables	9 Months Ended
	Sep. 30, 2024
Trade and other payables
Trade and other payables	8. Trade and other payables Trade and other payables consist of the following: September 30, 2024 December 31, 2023 $ $ Trade payables 1,349,552 3,240,658 Accrued liabilities (i) 1,958,384 954,371 3,307,936 4,195,029 (i) Accrued liabilities consist of the following: September 30, 2024 December 31, 2023 $ $ Operational expenses 1,343,340 71,953 Professional and other fees 205,851 473,225 Accrued interest 409,193 409,193 1,958,384 954,371

Warrants Liability

Warrants Liability	9 Months Ended
	Sep. 30, 2024
Warrants Liability
Warrants Liability	9. Warrants Liability In August 2020, the Company issued 42,499 Class B Subordinate Voting Shares and 21,250 warrants to purchase Class B Subordinate Voting Shares for total cash proceeds of $9,999,997. Each warrant is exercisable to purchase one Class B Subordinate Voting Share of the Company at an exercise price of $276.90 per share and expire five years from the date of issuance. The fair value of these warrants is classified as Level 2 in the fair value hierarchy. On initial recognition the Company determined that these warrants did not meet the IFRS definition of equity due to the exercise price being denominated in United States dollar, which was not the functional currency of the Company at the time resulting in variability in exercise price. The change in functional currency on October 1, 2020, was determined to be a change in circumstance and, as such, the Company has made an accounting policy choice to continue to recognize the warrants as a financial liability classified at fair value through profit or loss. The fair value of the warrants liability as at September 30, 2024, was $75 (December 31, 2023 – $31,338) resulting in a gain on change in fair value of $31,263 for the nine months ended September 30, 2024 (2023 – $113,211). The fair value was determined using the Black-Scholes option pricing model and the following assumptions as at: September 30, 2024 December 31, 2023 Share price $ 4.00 $ 59.80 Exercise price $ 276.90 $ 276.90 Expected dividend yield - - Risk free interest rate 2.94 % 3.91 % Expected life 0.85 1.60 Expected volatility 136 % 66 %

Notes payable

Notes payable	9 Months Ended
	Sep. 30, 2024
Notes payable
Notes payable	10. Notes payable As at September 30, 2024, the Company has total notes payable balance of $300,549 (December 31, 2023 - $300,549). During the nine months ended September 30, 2024, the Company issued a note payable of $290,387 (AUD $440,000) to RH Capital Finance CO LLC, with an interest rate of 16.0% per annum and maturing in June 2024. During the nine months ended September 30, 2024, the Company accrued interest of $30,547 (AUD $34,941). The total balance including interest was received during the nine months ended September 30, 2024, and there was no balance remaining as of September 30, 2024. This loan allowed the Company to access liquidity with respect to the Australian tax rebate scheme structure. The remaining note payable balance of $300,549 was assumed on acquisition of Prismic and is due on demand.

Share capital

Share capital	9 Months Ended
	Sep. 30, 2024
Share capital
Share capital	11. Share capital [a] Authorized The Company is authorized to issue an unlimited number of class A multiple voting shares ("Class A Multiple Voting Shares") and an unlimited number of class B subordinate voting shares ("Class B Subordinate Voting Shares"), all without par value. All shares are ranked equally regarding the Company's residual assets. The Class B Subordinate Voting Shares are “restricted securities” within the meaning of such term under applicable Canadian securities laws, as these securities do not carry equal voting rights as compared with the Class A Multiple Voting Shares. The holders of Class A Multiple Voting Shares are entitled to 276,660 votes per Class A Multiple Voting Share held. Class A Multiple Voting Shares are held by the Chief Executive Officer (“CEO”), President, Executive Co-Chairman of the Board and the Director and Executive Co-Chairman of the Board. The holders of Class B Subordinate Voting Shares are entitled to one (1) vote per share held. [b] Issued and outstanding During the nine months ended September 30, 2024, the Company consolidated its shares on a 65:1 basis, and the effect was applied retroactively for all comparative periods presented. Reconciliation of the Company’s share capital is as follows, adjusted for the share consolidation: Class A Multiple Voting Shares Class B Subordinate Voting Shares Warrants # $ # $ # $ Balance, December 31, 2022 2 151,588 592,372 143,258,972 99,725 2,142,400 Shares repurchase [a] — — (29,303 ) (7,165,356 ) — — Warrants issued [b] — — — — 61,154 1,330,043 PSU converted to shares [c] — — 41,848 1,464,000 — — Share options exercised [d] — — 323 33,247 — — Share-based payments [e] — — 280 16,000 — — Warrants expired [f] — — — — (2,047 ) (791,807 ) Balance, September 30, 2023 2 151,588 605,520 137,606,863 158,832 2,680,636 Balance, December 31, 2023 2 151,622 605,796 137,626,863 158,831 2,723,356 Shares issued [g] 10 79 956,935 9,185,073 — — Shares for debt [h] — — 292,477 1,983,728 — — Warrants expired [i] — — — — (20,769 ) (286,189 ) Share options exercised [j] — — 1,446 102,563 — — Warrants cancelled [k] — — — — (7,692 ) (439,408 ) RSU converted to shares [l] — — 7,500 31,009 — — Balance, September 30, 2024 12 151,701 1,864,154 148,929,236 130,370 1,997,759 Activity during the nine months ended September 30, 2023: [a] During the nine months ended September 30, 2023, the Company repurchased and canceled 29,303 Class B Subordinate Voting Shares at prevailing market prices as part of its share repurchase program. [b] During the nine months ended September 30, 2023, the Company issued 61,154 warrants for consulting services with a fair value of $1,384,969. The Company recognized $1,330,043 as expense during the nine months ended September 30, 2023, with the remaining $54,926 to be recognized over the vesting period of certain warrants. The Company determined the fair value of the services received could not be measured reliably and determined the fair value using the Black-Scholes model. [c] During the nine months ended September 30, 2023, the Company converted 41,848 PSUs to Class B Subordinate Voting Shares following the completion of the vesting condition on January 6, 2023, the filing of the MS Phase 1 IND. [d] During the nine months ended September 30, 2023, 323 share options were exercised with an exercise price of C$84.50 in exchange for 323 Class B Common shares. [e] During the nine months ended September 30, 2023, the Company issued 280 Class B Subordinate Voting Shares for services received during the period with a fair value of $16,000. [f] During the nine months ended September 30, 2023, 2,047 warrants expired unexercised. Activity during the nine months ended September 30, 2024: [g] During the nine months ended September 30, 2024, the Company entered into an at-the-market offering agreement (the “ATM Agreement”) to sell Class B Subordinate Voting Shares, having an aggregate offering price up to $11,154,232. During the nine months ended September 30, 2024, the Company issued 956,935 common shares for gross proceeds of $9,612,409. A cash commission of $288,373 based on 3.0% of the aggregate gross proceeds, plus other trading expenses of $138,963, resulted in total share issuance costs of $427,336. The net proceeds were $9,185,073. During the nine months ended September 30, 2024, the Company issued 10 Class A Multiple Voting Shares of the Company for total gross proceeds of approximately C$108. [h] In March 2024, the Company settled an aggregate of $524,324 (C$637,750) of amounts owing to an arm’s length creditor through the issuance of 9,231 Class B Subordinate Voting Shares at a price of $58.70 per Class B Subordinate Voting Share for total value of $541,800. Included in this amount is 846 Class B Subordinate Voting Shares issued pursuant to the conversion of RSUs, which vested immediately upon grant (Note 12). Each RSU entitled the holder to acquire one Class B Subordinate Voting Share of the Company upon vesting. The Company incurred a loss on settlement of debt of $17,476 as the share price on the date of issuance was higher than the price stated in the agreement. In February 2024, the Company issued 605 Class B Subordinate Voting Shares at a deemed price of $55.90 per Class B Subordinate Voting Share to settle an aggregate amount of $33,636 owing to an arm’s length creditor. In June 2024, the Company settled an aggregate of $109,614 (C$150,000) of amounts owing to arm’s length creditors through the issuance of 7,692 Class B Subordinate Voting Shares at a price of $14.25 per Class B Subordinate Voting Share for total value of $109,614. The agreements state that the creditors will accept shares as payment and settlement of debt, provided that upon selling the debt settlement shares, the creditors have received net proceeds from the sale equal to the debt. For any losses, if any, calculated as the total debt minus the net proceeds, shall be added back to the debt amount on a dollar-for-dollar basis by the amount of the loss. In July and August 2024, the Company issued a total of 22,308 Class B Subordinate Voting Shares to settle debts owing to two arm’s length creditors to settle an aggregate of $244,049 at prices ranging from $4.71 to $14.32 per share. As at September 30, 2024, there were amounts remaining in payables for these creditors. There were no gains or losses recognized. In July 2024, the Company issued a total of 2,308 Class B Subordinate Voting Shares to settle debts owing to an arm’s length creditor to settle an aggregate of $33,057 at a price of $14.32 per share. The Company recognized a gain on settlement of $12,321 and there were no amounts remaining in payables as at September 30, 2024. In July 2024, the Company issued a total of 2,173 Class B Subordinate Voting Shares to settle debts owing to an arm’s length creditor to settle an aggregate of $24,866 at a price of $11.44 per share. There were no amounts remaining in payables as at September 30, 2024. There were no gains or losses recognized. In September 2024, the Company completed debt settlements in the amount of $997,920 (C$1,350,000) to the Company’s executives through the issuance of 248,160 Class B Subordinate Voting Shares, at a deemed price of $4.02 (C$5.44) per Class B Subordinate Voting Share with a total value of $996,705. The difference was related to foreign exchange translation. [i] During the nine months ended September 30, 2024, 20,769 warrants expired unexercised. [j] During the nine months ended September 30, 2024, 1,446 share options were exercised with a price of $71.50 (C$97.50) in exchange for 1,446 Class B Common shares. The shares were issued in exchange for services. [k] On September 6, 2024, the Company cancelled an aggregate of 7,692 warrants with an exercise price of $97.50 to purchase Class B Subordinate Voting Shares, which were previously granted to a board member. [l] On September 6, 2024, the Company granted 7,500 RSUs to an arm’s length party with a price of $4.13 per unit for a total value of $31,009 based on the share price at the date of issuance. The total amount was recognized as share-based compensation expense as the RSUs vested immediately upon issuance and 7,500 Class B Subordinate Voting Shares were issued for the same value. The changes in the number of warrants outstanding during the nine months ended September 30, 2024, and 2023: Number of warrants Weighted average exercise price # C$ Outstanding as at December 31, 2022 99,725 356.20 Issued 61,154 295.75 Expired (2,047 ) 260.65 Outstanding as at September 30, 2023 158,832 333.45 Outstanding as at December 31, 2023 158,831 328.30 Cancelled (7,692 ) 97.50 Expired (20,769 ) 232.19 Outstanding as at September 30, 2024 130,370 399.64 Measurement of fair values There were no warrants granted during the nine months ended September 30, 2024. The fair value of the warrants issued during the nine months ended September 30, 2023, was estimated at the date of grant using the Black-Scholes option pricing model with the following inputs: 2023 Grant date share price C$93.60 - C$148.85 Exercise price C$97.50 - C$703.30 Expected dividend yield — Risk free interest rate 3.08% - 4.26% Expected life 0.75 - 5 years Expected volatility 64% - 109% The following table is a summary of the Company’s warrants outstanding as at September 30, 2024: Exercise price Number outstanding Expiry Date C$ # February 27, 2025 (i) 155.69 6,154 February 27, 2025 (i) 355.87 6,154 February 27, 2025 (i) 711.74 3,077 May 15, 2025 97.50 577 May 15, 2025 195.00 577 May 23, 2025 97.50 769 March24,2025 (i) 155.69 6,154 March24,2025 (i) 355.87 6,154 March24,2025 (i) 711.74 3,077 May 4, 2025 1,737.65 57 May 10, 2025 1,737.65 29 May 17, 2025 1,737.65 57 May 31, 2025 1,737.65 29 June 8, 2025 627.25 23,077 August 6, 2025 (i) 503.56 21,249 October 20, 2025 (i) 294.48 53,147 January 16, 2026 1,737.65 26 January 20, 2026 1,737.65 6 399.64 130,370 (i) Warrants were issued in US$

Sharebased compensation

Sharebased compensation	9 Months Ended
	Sep. 30, 2024
Sharebased compensation
Share-based compensation	12. Share-based compensation The Company has established a share option plan (the “Option Plan”) for directors, officers, employees and consultants of the Company. The Company’s Board determines, among other things, the eligibility of individuals to participate in the Option Plan, the term and vesting periods, and the exercise price of options granted to individuals under the Option Plan. Each share option converts into one common share of the Company on exercise. No amounts are paid or payable by the individual on receipt of the option. The options carry neither rights to dividends nor voting rights. Options may be exercised at any time from the date of vesting to the date of their expiry. [i] Share-based payment arrangements During the nine months ended September 30, 2024, the Company granted a total of 54,308 (2023 – 38,277) share options, consisting of 12,308 granted to consultants of the Company exercisable at a price of $97.50 per unit and 42,000 granted to directors and certain consultants of the Company exercisable at prices ranging from $5.25 to $5.69 per unit. During the nine months ended September 30, 2024, the Company cancelled an aggregate of 47,358 options, which were previously granted to board members, advisory board members, employees, advisors and consultants of the Company. During the nine months ended September 30, 2024, 33,368 (2023 – 3,516) share options related to former officers and employees who are no longer with the Company expired. Individuals who are no longer with the Company have 30 days after their last day to exercise any vested share options. Vested options that remain unexercised after 30 days expired. The changes in the number of share options outstanding during the nine months ended September 30, 2024, and 2023, were as follows: Number of options Weighted average exercise price # C$ Outstanding as at December 31, 2023 37,856 101.59 Granted 54,308 26.24 Exercised (1,446 ) 97.50 Cancelled (47,358 ) 95.84 Expired (904 ) 352.83 Outstanding as at September 30, 2024 42,456 6.97 Exercisable as at September 30, 2024 34,123 7.30 Number of options Weighted average exercise price # C$ Outstanding as at December 31, 2022 6,439 241.15 Granted 38,277 98.80 Forfeited (1,900 ) 135.85 Exercised (323 ) 84.50 Expired (3,516 ) 303.55 Outstanding as at September 30, 2023 38,977 102.70 Exercisable as at September 30, 2023 37,546 100.10 Measurement of fair values The fair value of share options granted during the nine months ended September 30, 2024, and 2023, were estimated at the date of grant using the Black-Scholes option pricing model with the following inputs: 2024 2023 Grant date share price C$2.84 - C$72.15 C$83.20 - $C161.20 Exercise price C$5.25 - C$97.50 C$84.50 - $C159.25 Expected dividend yield — — Risk free interest rate 2.91% - 4.20% 2.88% - 3.99% Expected life 2.00 years 2.91 – 5.00 years Expected volatility 66% - 103% 95% - 110% Expected volatility was estimated by using the annualized historical volatility of the Company. The expected option life represents the period that options granted are expected to be outstanding. The risk-free interest rate is based on Canadian government bonds with a remaining term equal to the expected life of the options. The following table is a summary of the Company’s share options outstanding as at September 30, 2024: Options outstanding Options exercisable Exercise price Number outstanding Weighted average remaining contractual life [years] Exercise price Number exercisable C$ # # C$ # 154.39 228 1.41 154.39 228 156.55 228 1.48 156.55 228 5.60 12,500 1.93 5.60 4,167 5.25 29,500 1.99 5.25 29,500 6.97 42,456 1.97 7.30 34,123 [ii] Performance Share Units (“PSUs”) and Restrictive Share Units (“RSUs”) In May 2022, the Company established a performance share unit plan (“PSU Plan”) and a restrictive unit plan (“RSU Plan”), for directors, offers, employees and consultants of the Company. The Company’s Board determines the eligibility of individuals to participate in the PSU Plan and RSU Plan to align their interests with those of the Company’s shareholders. No amounts are paid or payable by the individual on receipt of the PSUs and RSUs. Each PSU and RSU converts into one common share of the Company at $nil exercise price. The Company’s PSU Plan and RSU Plan provides that the number of common shares reserved for issuance may not exceed 10% of the aggregate number of common shares that are outstanding unless the Board has increased such limit by a Board resolution. PSUs There were no PSUs issued during the nine months ended September 30, 2024. As at September 30, 2024, there were no PSUs outstanding (December 31, 2023 – Nil). During the nine months ended September 30, 2023, the Company converted 41,848 PSUs to Class B Subordinate Voting Shares. The PSUs were fully vested as of January 6, 2023, upon the filing of the MS Phase 1 IND. During the nine months ended September 30, 2023, 1,538 PSUs related to a former independent director who are no longer with the Company was forfeited. RSUs On February 23, 2024, the Company granted 846 RSUs pursuant to the shares for debt transaction (Note 11). The RSUs vested immediately upon grant and 846 Class B Subordinate Voting Shares were issued with a total fair value of $49,665, which was determined based on the share price of the Company on the date of the grant. On August 23, 2024, the Company granted an aggregate of 32,690 RSUs at a price of $4.21 per unit for a total value of $137,625 based on the share price at the date of issuance. Each RSU granted vests the earlier of: (i) one year; and (ii) the successful implementation of the MS MAD study conducted by Ingenu of Australia, subject to acceleration in the event of a takeover bid or change of control. During the nine months ended September 30, 2024, the Company recognized $2,868 as share-based compensation expense and contributed surplus. On September 6, 2024, the Company granted 7,500 RSUs at a price of $4.13 per unit for a total value of $31,009 based on the share price at the date of issuance, which was recognized as share-based compensation expense. The RSUs vested immediately upon issuance and 7,500 Class B Subordinate Voting Shares were issued for the same value. The change in the number of RSUs during the nine months ended September 30, 2024, is as follows: Number of RSUs # Outstanding as at December 31, 2023 — Granted 41,036 Converted to common shares (8,346 ) Outstanding as at September 30, 2024 32,690 The Company recognized share-based compensation as follows for the three and nine months ended September 30, 2024, and 2023: For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 $ $ $ $ Share options 31,547 5,797 200,814 1,925,492 RSUs 33,877 — 33,877 — PSUs — — — 458,253 Shares for services — 16,000 — 16,000 Warrants for services — 98,063 — 1,330,043 Other (i) — 6,303 — 6,303 65,424 126,163 234,691 3,736,091 i) Share-based compensation related to share options and restricted share units issued by Celly and convertible into common shares of Celly.

Non-controlling interests

Non-controlling interests	9 Months Ended
	Sep. 30, 2024
Non-controlling interests
Non-controlling interests	13. Non-controlling interests Through the License Agreement, Quantum acquired 34.66% of Celly on July 31, 2023. As of September 30, 2024, the Company has a 24.15% (December 31, 2023 – 26.15%) ownership interest in Celly through common shares held in Celly. The non-controlling interest represents the common shares of Celly not attributable to the Company. Reconciliation of non-controlling interest is as follows: $ Balance, December 31, 2023 (327,501 ) Net loss for the period (616,790 ) Balance, September 30, 2024 (944,291 )

Loss per share

Loss per share	9 Months Ended
	Sep. 30, 2024
Loss per share
Loss per share	14. Loss per share Net loss per common share represents net loss attributable to common shareholders divided by the weighted average number of common shares outstanding during the period. For all the periods presented, diluted loss per share equals basic loss per share due to the anti-dilutive effect of warrants, share options, PSUs and RSUs. The outstanding number and type of securities that could potentially dilute basic net loss per share in the future but would have decreased the loss per share (anti-dilutive) for the nine months ended September 30, 2024, and 2023, are as follows: September 30, 2024 September 30, 2023 # # Warrants 130,370 158,831 Share Options 42,456 38,977 RSUs 32,690 — 205,516 197,808

General and administrative

General and administrative	9 Months Ended
	Sep. 30, 2024
General and administrative
General and administrative	15. General and administrative Components of general and administrative expenses for the three and nine months ended September 30, 2024, and 2023 were as follows: For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 $ $ $ $ Professional fees 618,906 977,628 2,435,706 2,386,402 Investor relations 543,327 248,206 1,376,543 595,756 Salaries, wages and benefits 1,409,817 352,256 2,225,956 1,448,182 Consulting fees 281,326 247,542 704,779 1,073,413 Office and general administrative 288,702 734,146 638,731 2,047,564 Foreign exchange loss (gain) 107,952 512,111 97,810 108,107 3,250,030 3,071,889 7,479,525 7,659,424

Segment information

Segment information	9 Months Ended
	Sep. 30, 2024
Segment information
Segment information	16. Segment information Reportable segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker, with appropriate aggregation. The chief operating decision maker is the CEO who is responsible for allocating resources, assessing the performance of the reportable segment and making key strategic decisions. The Company operates in two segments: Biopharmaceutical and Strategic Investments. The Company’s Biopharmaceutical segment is focused on furthering the research and development of the Company’s drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Biopharmaceutical segment primarily earns interest income on excess cash on hand invested in short-term guaranteed investment certificates. The Company’s Strategic Investments segment is focused on generating returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The following tables summarize the Company's total current and non-current assets and current and non-current liabilities as of September 30, 2024, and December 31, 2023, on a segmented basis: As at September 30, 2024 Biopharmaceutical Strategic Investments Total $ $ $ Current assets 6,860,179 6,983,513 13,843,692 Non-current assets 5,183,110 — 5,183,110 Current liabilities 3,681,035 — 3,681,035 Non-current liabilities — — — As at December 31, 2023 Biopharmaceutical Strategic Investments Total $ $ $ Current assets 3,897,317 7,187,988 11,085,305 Non-current assets 5,482,157 907,366 6,389,523 Current liabilities 4,565,566 — 4,565,566 Non-current liabilities — — — The following tables summarize the Company's interest income, total operating expenses, and net loss for the three and nine months ended September 30, 2024 and 2023 on a segmented basis: For the nine months ended September 30, 2024 Biopharmaceutical Strategic Investments Total $ $ $ Interest expense (income) (1,998 ) (438,818 ) (440,816 ) Total operating expenses 9,894,725 307 9,895,032 Net (loss) income (9,897,762 ) 438,511 (9,459,251 ) For the three months ended September 30, 2024 Biopharmaceutical Strategic Investments Total $ $ $ Interest expense (income) (14,107 ) (149,761 ) (163,868 ) Total operating expenses 4,181,008 62 4,181,070 Net (loss) income (4,165,026 ) 149,699 (4,015,327 ) For the nine months ended September 30, 2023 Biopharmaceutical Strategic Investments Consolidated $ $ $ Interest income (193,848 ) (438,724 ) (632,572 ) Total operating expenses 21,988,188 184 21,988,372 Net (loss) income (17,017,562 ) 438,540 (16,579,022 ) For the three months ended September 30, 2023 Biopharmaceutical Strategic Investments Consolidated $ $ $ Interest income (22,545 ) (151,523 ) (174,068 ) Total operating expenses 3,311,874 3 3,311,877 Net (loss) income (1,951,904 ) 820,704 (1,131,200 )

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and contingencies
Commitments and contingencies	17. Commitments and contingencies Commitments Lucid-MS Agreement The Company has entered into a license agreement that governs the Lucid-MS compound. Under the terms of the agreement, the Company shall pay a yearly license maintenance fee of C$100,000 until the first commercial sale of a product is made. Under the agreement the Company is committed to minimum milestone payments of $nil and maximum milestone payments of C$12,500,000 if all product development and regulatory milestones are met. Furthermore, the Company is also responsible to pay revenue milestone payments and royalties if revenue milestones from commercial sales are achieved. Milestones can be extended by mutual agreement. No payments have been made to date related to these milestones. Contingencies Legal Matters From time to time, the Company is named as a party to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the difference will be accounted for as a charge to the condensed consolidated interim statements of loss and comprehensive loss in that period. GBB Drink Lab, Inc. GBB Drink Lab, Inc. (“GBB”) has filed a complaint with the United States District Court of Southern District of Florida, Fort Lauderdale Division against FSD Biosciences, Inc. and Quantum, claiming a material breach of a mutual non-disclosure agreement and misappropriation of trade secrets, which GBB claims has and continues to cause irreparable harm, valued, as of August 30, 2022 (prior to the misappropriation and material breach) at $53,047,000. On June 23, 2023, the Company filed a motion to dismiss the complaint. On July 3, 2023, GBB responded in opposition to the Company’s motion to dismiss the complaint. On August 24, 2023, the parties filed a proposed joint scheduling report with the U.S. District Court, which set forth various deadlines that would govern this action. Under the proposed joint schedule, which still needs to be approved by the U.S. District Court, the case would be trial-ready by June 2025. The ultimate outcome of the matter cannot be determined at this time. Raza Bokhari On July 15, 2021, the Company’s former CEO, Raza Bokhari, filed a notice of arbitration seeking relief and support for breach of contract and severance and damages in the amount of $30,200,000, for aggravated and punitive damages in the amount of $500,000 and legal fees and disbursements associated with the arbitration. Raza Bokhari was placed on administrative leave from his role as the Company’s Chief Executive Officer following the Company’s annual general and special meeting of shareholders on May 14, 2021, pending the outcome of an investigation of various concerns by a Special Committee comprised of independent directors using independent legal counsel. Upon the recommendation of the Special Committee, Raza Bokhari’s employment was terminated for cause by the Company’s board on July 27, 2021. The Company disputed the allegations and counterclaimed against Raza Bokhari for losses sustained as a result of his alleged breaches of his duties to the Corporation. The arbitration hearing concluded in August 2022 and the arbitrator issued his decision in November 2022. Raza Bokhari’s claim for USD $30.2 million was dismissed in its entirety along with his claim that he had been wrongfully dismissed. The arbitrator ordered that Raza Bokhari repay certain monies to Quantum, while also holding him responsible for Quantum’s costs of the arbitration. On December 9, 2022, Raza Bokhari filed an application in the Ontario Superior Court seeking to set aside the arbitral award of the court on the grounds that he was not treated equally and fairly and the arbitrator’s written award provided inadequate reasons for his decision. On December 20, 2022, the Company’s legal counsel wrote to the Commercial List of the Ontario Superior Court of Justice seeking to transfer the application from the Civil List to the Commercial List. The request was granted on January 12, 2023. On April 28, 2023, the court ordered the case to be heard at the Commercial List on September 27, 2023. On September 27 and 28, 2023, the application to set aside the award and cost of ground of unfairness was dismissed. As Raza Bokhari lost the set aside application, the court ordered Raza Bokhari to pay the Company C$165,000 to cover the Company’s legal expenses. On October 13, 2023, Raza Bokhari filed a “Notice of Motion for Leave to Appeal” with the Court of Appeal for Ontario. On December 15, 2023, the Company submitted a responding party’s factum to the Court of Appeal for Ontario. On February 6, 2024, the Ontario Superior Court of Justice affirmed the judgment and awarded an additional C$5,000 in costs considering Raza Bokhari’s failed motion for leave to appeal. As of the date hereof, the litigation is ongoing. On May 31, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed Quantum’s Petition to Confirm Arbitration Awards entered against Dr. Raza Bokhari. On June 27, 2024, the US District Court for the Eastern District of Pennsylvania confirmed Quantum’s motion for entry of judgment and granted judgment in favor of Quantum of approximately USD 3 million.

Related party transactions

Related party transactions	9 Months Ended
	Sep. 30, 2024
Related party transactions
Related party transactions	18. Related party transactions Related parties and related party transactions impacting the accompanying financial statements are summarized below and include transactions with the following individuals or entities: Key management personnel Related parties include directors, officers, close family members, certain consultants and enterprises that are controlled by these individuals as well as certain persons performing similar functions. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company. Transactions with key management and directors comprised of the following: a) Director’s compensation for the three and nine months ended September 30, 2024, was $31,294 and $131,010, respectively (2023 – $38,183 and $142,528). b) During the nine months ended September 30, 2024, the Company granted Nil (2023 – 6,154) PSUs to independent members of the Board. As at September 30, 2024, the PSUs had fully vested upon the filing of the MS Phase 1 IND on January 6, 2023 and were settled with the issuance of Class B Subordinate Voting Shares. c) During the nine months ended September 30, 2024, the Company granted the previous interim CEO, the current CEO, the Chief Operating Officer (“COO”) and the CEO of Lucid, Nil (2023 – 7,692) share options each with an exercise price of C$84.50 and an expiry date of January 25, 2028. All options were fully vested on grant. Each share option can be exercised to acquire one Class B Subordinate Voting Share. d) During the nine months ended September 30, 2024, the Company issued 10 Class A Multiple Voting Shares for aggregate gross proceeds of approximately C$108 to Xorax Family Trust (“Xorax”), a trust of which Zeeshan Saeed, the Chief Executive Officer and Co- Chairman of Quantum is a beneficiary, and Fortius Research and Trading Corp. (“Fortius”), a corporation controlled by Anthony Durkacz, a Co-Chairman of Quantum. On August 15, 2024, the Company closed a non-brokered private placement and issued 4 Class A Multiple Voting Shares at a price of C$18 per Class A Multiple Voting Share for aggregate gross proceeds of C$72 to Xorax and Fortius, with each entity receiving 2 Class A Multiple Voting Shares. On September 13, 2024, the Company closed a non-brokered private placement and issued 6 Class A Multiple Voting Shares at a price of $6 per Class A Multiple Voting Share for gross proceeds of C$36 to Xorax and Fortius, with each entity receiving 3 Class A Multiple Voting Shares. The participation by such insiders in each of the private placements is considered a “related-party transaction” within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions e) During the nine months ended September 30, 2023, the Company entered into a secured loan agreement with the CEO for C$1,200,000, with monthly payments of C$6,000 based on an annual interest rate of 6%. The loan matures on April 26, 2025, and is part of FSD Strategic Investments’ portfolio of loans. The loan is secured by a second charge mortgage on the underlying residential property. During the nine months ended September 30, 2024, a payment of C$400,000 was made by the CEO. f) During the nine months ended September 30, 2023, the Company issued 1,539 warrants for consulting services to certain independent members of the Board of Directors with a fair value of $533,206, prior to them joining the Board of Directors. The Company determined the fair value of the services received could not be measured reliably and determined the fair value using the Black-Scholes model. Key management personnel compensation during the three and nine months ended September 30, 2024, and 2023 is comprised of: For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 $ $ $ $ Salaries, benefits, bonuses and consulting fees 1,217,268 374,667 1,693,796 1,047,111 Share-based payments 21,530 — 2,366,146 1,963,983 1,238,798 374,667 4,059,942 3,011,094 As at September 30, 2024, the Company owed an executive officer $Nil (December 31, 2023 - $140,012), for legal fees incurred by the Company and paid by the executive officer on behalf of the Company. The amount owed is recorded within trade and other payables. As at September 30, 2024, the Company has $Nil owing to related parties included in accounts payable and accrued liabilities (December 31, 2023 - $Nil).

Capital Management

Capital Management	9 Months Ended
	Sep. 30, 2024
Capital Management
Capital Management	19. Capital Management The Company’s capital management objectives are to maintain financial flexibility to complete the research and development of a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The Company defines capital as the aggregate of its capital stock and borrowings. As at September 30, 2024, the Company’s share capital was $149,080,937 (December 31, 2023 – $137,778,485). The Company does not have any long-term debt. Outstanding notes payables were assumed on the acquisition of Prismic and are due on demand. The Company manages its capital structure in accordance with changes in economic conditions. To maintain or adjust its capital structure, the Company may elect to issue or repay financial liabilities, issue shares, repurchase shares or undertake any other activities as deemed appropriate under specific circumstances. The Company is not subject to any externally imposed capital requirements.

Subsequent events

Subsequent events	9 Months Ended
	Sep. 30, 2024
Subsequent events
Subsequent events	20. Subsequent Events On October 7, 2024, the Company announced that Celly had signed a Master Distribution Agreement with FUSION Distribution Group for unbuzzd™, its alcohol metabolism beverage product, across Puerto Rico, the Caribbean, and parts of Central and South America. The product was available in Ready-to-Mix powder format on Amazon, with Ready-to-Drink cans planned for future release through FUSION's distribution network. On October 20, 2024, the Company filed a complaint in the U.S. District Court for the Southern District of New York against CIBC World Markets, Inc., RBC Dominion Securities Inc., and John Does 1-10. The complaint alleges market manipulation through spoofing activities between January 1, 2020, and August 15, 2024, seeking damages exceeding USD 700 million related to the sale of approximately 90 million shares. The matter is currently in its initial legal proceedings phase. On October 29, 2024, the Company announced that its subsidiary, Huge Biopharma Australia Pty Ltd, had initiated sentinel dosing in a Phase 1 clinical trial for Lucid-MS, a potential multiple sclerosis treatment, in Australia. The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and pharmacokinetics of Lucid-MS in healthy adult participants, marking a significant step toward Phase-2 efficacy trials. On October 31, 2024, the Company successfully further reduced its outstanding debt to a creditor, which was previously reported in the balance sheet at approximately $611,000. The debt has been reduced to approximately $211,000, representing a significant reduction of approximately $400,000. On November 5, 2024, the Company successfully settled its total outstanding debt to a creditor, which was previously reported on the balance sheet at approximately $278,000.

Basis of presentation (Policies

Basis of presentation (Policies)	9 Months Ended
	Sep. 30, 2024
Basis of presentation
Statement of compliance	These condensed consolidated interim financial statements (“financial statements”) were prepared using the same accounting policies and methods as those used in the Company’s audited consolidated financial statements for the year ended December 31, 2023. These financial statements have been prepared in compliance with IAS 34 – Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). Accordingly, certain disclosures normally included in annual financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) have been omitted or condensed. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2023. These financial statements were approved and authorized for issuance by the Board of Directors (the “Board”) of the Company on November 5, 2024.
Functional currency and presentation currency	The financial statements of each company within the consolidated group are measured using their functional currency, which is the currency of the primary economic environment in which an entity operates. These condensed consolidated interim financial statements are presented in United States dollars ("USD"), which is the Company’s functional and presentation currency for all periods presented. The Company’s functional currency is the United States dollar and the functional currencies of its subsidiaries are as follows: FSD Biosciences Inc. United States Dollar Prismic Pharmaceuticals Inc. United States Dollar FV Pharma Inc. Canadian Dollar Lucid Psycheceuticals Inc. Canadian Dollar FSD Strategic Investments Inc. Canadian Dollar FSD Pharma Australia Pty Ltd Australian Dollar Celly Nutrition Corp. Canadian Dollar Huge Biopharma Australia Pty Ltd Australian Dollar
Use of estimates and judgments	The preparation of these financial statements in conformity with IFRS requires management to make estimates, judgements and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, consistent with those disclosed in the audited consolidated financial statements for the year ended December 31, 2023, and described in these financial statements. Actual results could differ from these estimates. Estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Disclosure of interests in other entities To assess the investment in Celly, judgment was required to determine if the Company has significant influence or control of Celly. The Company considered the relevant guidance in IFRS 10 – Consolidated Financial Statements, IAS 24 – Related Party Disclosures and IAS – 28 Investments in Associates and Joint Ventures. Judgment is applied in determining when the Company controls an investment even if the Company holds less than a majority of the investee’s voting rights (the existence of de facto control). The Company concluded it has control of Celly even though the Company only held 24.15% of the voting rights as of September 30, 2024 (December 31, 2023 – 26.15%). The Company concluded it has control of Celly as the Company, together with persons or entities considered to be de facto agents of the Company, held a combined 63.65% (December 31, 2023 - 52.05%) of the voting rights of Celly. In addition, key management personnel of the Company hold three of the four board of director positions of Celly. The assessment of control is performed on a continuous basis. The Company determined that it obtained control of Celly on July 31, 2023, and control was maintained from July 31, 2023, through September 30, 2024. Celly is significantly dependent on the Company as a result of the License Agreement and the loan. The NCI component of Celly is included as a separate component in equity (Note 13).
New standards, amendments and interpretations not yet adopted by the Company	IFRS 16 – Leases (“IFRS 16”) In September 2022, the IASB issued amendments to IFRS 16, Leases, which add to requirements explaining how a company accounts for a sale and leaseback after the date of the transaction. The amendments are effective for annual reporting periods beginning on or after January 1, 2024. Earlier application is permitted. The amendment did not have a material impact on the financial statements. All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the financial statements.

Nature of business (Tables)

Nature of business (Tables)	9 Months Ended
	Sep. 30, 2024
Nature of business
Schedule of ownership percentage in subsidiaries	Ownership percentage as at Ownership percentage as at Entity Name Country September 30, 2024 December 31, 2023 % % FSD Biosciences Inc. USA 100.00 100.00 Prismic Pharmaceuticals Inc. USA 100.00 100.00 FV Pharma Inc. Canada 100.00 100.00 Lucid Psycheceuticals Inc. Canada 100.00 100.00 FSD Strategic Investments Inc. Canada 100.00 100.00 FSD Pharma Australia Pty Ltd Australia 100.00 100.00 Celly Nutrition Corp. Canada 24.15 26.15 Huge Biopharma Australia Pty Ltd Australia 100.00 -

Other receivables (Tables)

Other receivables (Tables)	9 Months Ended
	Sep. 30, 2024
Other receivables
Schedule of other receivables	September 30, 2024 December 31, 2023 $ $ Sales tax recoverable 70,478 209,550 Interest receivable 28,852 15,511 Other receivables 4,874 3,703 104,204 228,764

Prepaid expenses and deposits (

Prepaid expenses and deposits (Tables)	9 Months Ended
	Sep. 30, 2024
Prepaid expenses and deposits
Schedule of prepaid expenses and deposits	September 30, 2024 December 31, 2023 $ $ Research and development 46,809 30,705 Insurance 58,708 60,999 Other prepaids and deposits 44,808 63,709 150,325 155,413

Finance receivables (Tables)

Finance receivables (Tables)	9 Months Ended
	Sep. 30, 2024
Finance receivables
Schedule of finance receivables	$ Balance – January 1, 2024 8,095,354 Add: Additions 2,452,033 Add: Interest income 397,939 Less: Interest payments (367,346 ) Less: Principal payments (3,390,767 ) Effects of foreign exchange (203,700 ) Balance – September 30, 2024 6,983,513 Current 6,983,513 Non-current - Balance – September 30, 2024 6,983,513 $ Minimum payments receivable 6,647,037 Unearned income 336,476 Net investment 6,983,513 Allowance for credit losses — Finance receivables, net 6,983,513

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Investments
Schedule of investments	Entity Instrument Note Balance at December 31, 2023 Additions Redemptions Effects of foreign exchange Balance at September 30 , 2024 $ $ $ $ A2ZCryptoCap Inc. Shares (i) 6,049 — — (123 ) 5,926 Royal Bank of Canada GIC (ii) 756,100 — (738,000 ) (18,100 ) — Royal Bank of Canada GIC (iii) — 2,985,424 — — 2,985,424 Bank of Montreal GIC (iv) — 500,000 — — 500,000 762,149 3,485,424 (738,000 ) (18,223 ) 3,491,350 Current 3,485,424 Non-Current 5,926 3,491,350

Intangible assets (Tables)

Intangible assets (Tables)	9 Months Ended
	Sep. 30, 2024
Intangible assets
Schedule of intangible assets	Cost Innovet Prismic Lucid Total As at December 31, 2022 750,000 19,201,493 6,314,571 26,266,064 Impairment (750,000 ) (19,201,493 ) — (19,951,493 ) As at December 31, 2023 and September 30, 2024 — — 6,314,571 6,314,571 Accumulated amortization As at December 31, 2022 229,933 13,457,622 538,220 14,225,775 Amortization 39,971 1,904,348 420,664 2,364,983 Impairment (269,904 ) (15,361,970 ) — (15,631,874 ) As at December 31, 2023 — — 958,884 958,884 Amortization — — 315,786 315,786 As at September 30, 2024 — — 1,274,670 1,274,670 Net book value As at December 31, 2023 — — 5,355,687 5,355,687 As at September 30, 2024 — — 5,039,901 5,039,901

Trade and other payables (Table

Trade and other payables (Tables)	9 Months Ended
	Sep. 30, 2024
Trade and other payables
Schedule of trade and other payables	September 30, 2024 December 31, 2023 $ $ Trade payables 1,349,552 3,240,658 Accrued liabilities (i) 1,958,384 954,371 3,307,936 4,195,029
Schedule of accrued liabilities	September 30, 2024 December 31, 2023 $ $ Operational expenses 1,343,340 71,953 Professional and other fees 205,851 473,225 Accrued interest 409,193 409,193 1,958,384 954,371

Warrants Liability (Tables)

Warrants Liability (Tables)	9 Months Ended
	Sep. 30, 2024
Warrants Liability
Schedule of fair black scholes warrants liability	September 30, 2024 December 31, 2023 Share price $ 4.00 $ 59.80 Exercise price $ 276.90 $ 276.90 Expected dividend yield - - Risk free interest rate 2.94 % 3.91 % Expected life 0.85 1.60 Expected volatility 136 % 66 %

Share capital (Tables)

Share capital (Tables)	9 Months Ended
	Sep. 30, 2024
Share capital
Schedule of changes in share capital	Class A Multiple Voting Shares Class B Subordinate Voting Shares Warrants # $ # $ # $ Balance, December 31, 2022 2 151,588 592,372 143,258,972 99,725 2,142,400 Shares repurchase [a] — — (29,303 ) (7,165,356 ) — — Warrants issued [b] — — — — 61,154 1,330,043 PSU converted to shares [c] — — 41,848 1,464,000 — — Share options exercised [d] — — 323 33,247 — — Share-based payments [e] — — 280 16,000 — — Warrants expired [f] — — — — (2,047 ) (791,807 ) Balance, September 30, 2023 2 151,588 605,520 137,606,863 158,832 2,680,636 Balance, December 31, 2023 2 151,622 605,796 137,626,863 158,831 2,723,356 Shares issued [g] 10 79 956,935 9,185,073 — — Shares for debt [h] — — 292,477 1,983,728 — — Warrants expired [i] — — — — (20,769 ) (286,189 ) Share options exercised [j] — — 1,446 102,563 — — Warrants cancelled [k] — — — — (7,692 ) (439,408 ) RSU converted to shares [l] — — 7,500 31,009 — — Balance, September 30, 2024 12 151,701 1,864,154 148,929,236 130,370 1,997,759
Schedule of changes in warrants outstanding and weighted average exercise price	Number of warrants Weighted average exercise price # C$ Outstanding as at December 31, 2022 99,725 356.20 Issued 61,154 295.75 Expired (2,047 ) 260.65 Outstanding as at September 30, 2023 158,832 333.45 Outstanding as at December 31, 2023 158,831 328.30 Cancelled (7,692 ) 97.50 Expired (20,769 ) 232.19 Outstanding as at September 30, 2024 130,370 399.64
Schedule of fair value assumptions of warrants outstanding	2023 Grant date share price C$93.60 - C$148.85 Exercise price C$97.50 - C$703.30 Expected dividend yield — Risk free interest rate 3.08% - 4.26% Expected life 0.75 - 5 years Expected volatility 64% - 109%
Schedule of number of warrants outstanding and exercise price	Exercise price Number outstanding Expiry Date C$ # February 27, 2025 (i) 155.69 6,154 February 27, 2025 (i) 355.87 6,154 February 27, 2025 (i) 711.74 3,077 May 15, 2025 97.50 577 May 15, 2025 195.00 577 May 23, 2025 97.50 769 March24,2025 (i) 155.69 6,154 March24,2025 (i) 355.87 6,154 March24,2025 (i) 711.74 3,077 May 4, 2025 1,737.65 57 May 10, 2025 1,737.65 29 May 17, 2025 1,737.65 57 May 31, 2025 1,737.65 29 June 8, 2025 627.25 23,077 August 6, 2025 (i) 503.56 21,249 October 20, 2025 (i) 294.48 53,147 January 16, 2026 1,737.65 26 January 20, 2026 1,737.65 6 399.64 130,370

Share-based compensation (Table

Share-based compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Sharebased compensation
Schedule of stock options granted	Number of options Weighted average exercise price # C$ Outstanding as at December 31, 2023 37,856 101.59 Granted 54,308 26.24 Exercised (1,446 ) 97.50 Cancelled (47,358 ) 95.84 Expired (904 ) 352.83 Outstanding as at September 30, 2024 42,456 6.97 Exercisable as at September 30, 2024 34,123 7.30 Number of options Weighted average exercise price # C$ Outstanding as at December 31, 2022 6,439 241.15 Granted 38,277 98.80 Forfeited (1,900 ) 135.85 Exercised (323 ) 84.50 Expired (3,516 ) 303.55 Outstanding as at September 30, 2023 38,977 102.70 Exercisable as at September 30, 2023 37,546 100.10
Schedule of fair values of options granted using the Black-Scholes option pricing model	2024 2023 Grant date share price C$2.84 - C$72.15 C$83.20 - $C161.20 Exercise price C$5.25 - C$97.50 C$84.50 - $C159.25 Expected dividend yield — — Risk free interest rate 2.91% - 4.20% 2.88% - 3.99% Expected life 2.00 years 2.91 – 5.00 years Expected volatility 66% - 103% 95% - 110%
summary of Companyshare options outstanding	Options outstanding Options exercisable Exercise price Number outstanding Weighted average remaining contractual life [years] Exercise price Number exercisable C$ # # C$ # 154.39 228 1.41 154.39 228 156.55 228 1.48 156.55 228 5.60 12,500 1.93 5.60 4,167 5.25 29,500 1.99 5.25 29,500 6.97 42,456 1.97 7.30 34,123
Schedule of fair values of PSUs granted using the Black-Scholes option pricing model	Number of RSUs # Outstanding as at December 31, 2023 — Granted 41,036 Converted to common shares (8,346 ) Outstanding as at September 30, 2024 32,690
Schedule of share-based compensation	For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 $ $ $ $ Share options 31,547 5,797 200,814 1,925,492 RSUs 33,877 — 33,877 — PSUs — — — 458,253 Shares for services — 16,000 — 16,000 Warrants for services — 98,063 — 1,330,043 Other (i) — 6,303 — 6,303 65,424 126,163 234,691 3,736,091

Non-controlling interests (Tabl

Non-controlling interests (Tables)	9 Months Ended
	Sep. 30, 2024
Non-controlling interests
Schedule of reconciliation of non controlling interest	$ Balance, December 31, 2023 (327,501 ) Net loss for the period (616,790 ) Balance, September 30, 2024 (944,291 )

Loss per share (Tables)

Loss per share (Tables)	9 Months Ended
	Sep. 30, 2024
Loss per share
Schedule of loss per share	September 30, 2024 September 30, 2023 # # Warrants 130,370 158,831 Share Options 42,456 38,977 RSUs 32,690 — 205,516 197,808

General and administrative (Tab

General and administrative (Tables)	9 Months Ended
	Sep. 30, 2024
General and administrative
Schedule of general and administrative expense	For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 $ $ $ $ Professional fees 618,906 977,628 2,435,706 2,386,402 Investor relations 543,327 248,206 1,376,543 595,756 Salaries, wages and benefits 1,409,817 352,256 2,225,956 1,448,182 Consulting fees 281,326 247,542 704,779 1,073,413 Office and general administrative 288,702 734,146 638,731 2,047,564 Foreign exchange loss (gain) 107,952 512,111 97,810 108,107 3,250,030 3,071,889 7,479,525 7,659,424

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment information
Schedule of asset and income by segment	As at September 30, 2024 Biopharmaceutical Strategic Investments Total $ $ $ Current assets 6,860,179 6,983,513 13,843,692 Non-current assets 5,183,110 — 5,183,110 Current liabilities 3,681,035 — 3,681,035 Non-current liabilities — — — As at December 31, 2023 Biopharmaceutical Strategic Investments Total $ $ $ Current assets 3,897,317 7,187,988 11,085,305 Non-current assets 5,482,157 907,366 6,389,523 Current liabilities 4,565,566 — 4,565,566 Non-current liabilities — — — For the nine months ended September 30, 2024 Biopharmaceutical Strategic Investments Total $ $ $ Interest expense (income) (1,998 ) (438,818 ) (440,816 ) Total operating expenses 9,894,725 307 9,895,032 Net (loss) income (9,897,762 ) 438,511 (9,459,251 ) For the three months ended September 30, 2024 Biopharmaceutical Strategic Investments Total $ $ $ Interest expense (income) (14,107 ) (149,761 ) (163,868 ) Total operating expenses 4,181,008 62 4,181,070 Net (loss) income (4,165,026 ) 149,699 (4,015,327 ) For the nine months ended September 30, 2023 Biopharmaceutical Strategic Investments Consolidated $ $ $ Interest income (193,848 ) (438,724 ) (632,572 ) Total operating expenses 21,988,188 184 21,988,372 Net (loss) income (17,017,562 ) 438,540 (16,579,022 ) For the three months ended September 30, 2023 Biopharmaceutical Strategic Investments Consolidated $ $ $ Interest income (22,545 ) (151,523 ) (174,068 ) Total operating expenses 3,311,874 3 3,311,877 Net (loss) income (1,951,904 ) 820,704 (1,131,200 )

Related party transactions (Tab

Related party transactions (Tables)	9 Months Ended
	Sep. 30, 2024
Related party transactions
Schedule of key management personnel compensation	For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 $ $ $ $ Salaries, benefits, bonuses and consulting fees 1,217,268 374,667 1,693,796 1,047,111 Share-based payments 21,530 — 2,366,146 1,963,983 1,238,798 374,667 4,059,942 3,011,094

Nature of business (Details)

Nature of business (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Lucid Psycheceuticals Inc. [Member]
Statement [Line Items]
Country	Canada
Ownership percentage	100%	100%
FSD Biosciences Inc. [Member]
Statement [Line Items]
Country	USA
Ownership percentage	100%	100%
FV Pharma Inc.
Statement [Line Items]
Country	Canada
Ownership percentage	100%	100%
FSD Strategic Investments Inc.
Statement [Line Items]
Country	Canada
Ownership percentage	100%	100%
FSD Pharma Australia Pty Ltd [Member]
Statement [Line Items]
Country	Australia
Ownership percentage	100%	100%
Celly Nutrition Corp. [Member]
Statement [Line Items]
Country	Canada
Ownership percentage	24.15%	26.15%
Prismic Pharmaceuticals Inc. [Member]
Statement [Line Items]
Country	USA
Ownership percentage	100%	100%
Huge Biopharma Australia Pty Ltd
Statement [Line Items]
Country	Australia
Ownership percentage	100%	0%

Nature of business (Details Nar

Nature of business (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2023	Jul. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Statement [Line Items]
Accumulated deficit			$ (166,750,621)		$ (157,908,160)
Net loss			(9,459,251)	$ 16,579,022
Working capital surplus			$ 10,162,657		$ 6,519,739
FSD received common shares		200,000,000
Common share-split		2:1 share-split
Common shares issue		200,000,000
Acquired share percent		34.66%
Gross proceeds		$ 1,000,000
Distribution description	Company distributed 703,270 of its 3,076,923 shares of Celly to its shareholders.
Accrued interest rate	10%
Common shares deemed outstanding		25%
Celly Nutrition Corp. [Member]
Statement [Line Items]
Ownership percentage			24.15%		26.15%

Other receivables (Details)

Other receivables (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Other receivables
Sales tax recoverable	$ 70,478	$ 209,550
Interest receivable	28,852	15,511
Other receivables	4,874	3,703
Other receivables Net	$ 104,204	$ 228,764

Prepaid expenses and deposits_2

Prepaid expenses and deposits (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Prepaid expenses and deposits
Research and development	$ 46,809	$ 30,705
Insurance	58,708	60,999
Other prepaids and deposits	44,808	63,709
Prepaid expenses and deposits	$ 150,325	$ 155,413

Finance receivables (Details)

Finance receivables (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024
Finance receivables
Balance - January 1, 2024	$ 8,095,354
Add: Interest income	397,939
Add: Additions	2,452,033
Less: Interest payments	367,346
Less: Principal payments	3,390,767
Effects of foreign exchange	203,700
Balance - September 30, 2024	6,983,513
Current	6,983,513
Non-current	0
Balance - September 30, 2024	$ 6,983,513

Finance receivables (Details 1)

Finance receivables (Details 1)	Sep. 30, 2024 USD ($)
Finance receivables
Minimum payments receivable	$ 6,647,037
Unearned income	336,476
Net investment	6,983,513
Allowance for credit losses	0
Finance receivables, net	$ 6,983,513

Investments (Details)

Investments (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Statement [Line Items]
Begining balance	$ 762,149
Current	3,485,424	$ 756,100
Non current	5,926
Additions	3,485,424
Redemptions	(738,000)
Effects of foreign exchange	(18,223)
Ending balance	3,491,350
Bank of Montreal [Member] | Guaranteed Investment Certificate [Member]
Statement [Line Items]
Begining balance	0
Additions	500,000
Effects of foreign exchange	0
Ending balance	500,000
A2ZCryptoCap Inc. [Member] | Ordinary Stock Shares Member
Statement [Line Items]
Begining balance	6,049
Additions	0
Redemptions	0
Effects of foreign exchange	(123)
Ending balance	5,926
Royal Bank Of Canada [Member] | Guaranteed Investment Certificate Member
Statement [Line Items]
Begining balance	756,100
Additions	0
Redemptions	(738,000)
Effects of foreign exchange	(18,100)
Ending balance	0
Royal Bank Of Canada One [Member] | Guaranteed Investment Certificate One Member
Statement [Line Items]
Begining balance	0
Additions	2,985,424
Redemptions	0
Effects of foreign exchange	0
Ending balance	$ 2,985,424

Investments (Details Narrative)

Investments (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
	Aug. 09, 2023	Jun. 23, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 06, 2024	Jul. 31, 2024	Dec. 31, 2023
Statement [Line Items]
Shares price per shares					$ 4.13	$ 11.44
Purchase of notes			$ 3,485,424	$ 744,500
A2ZCryptoCap Inc. [Member]
Statement [Line Items]
Shares price per shares		$ 0.10					$ 0.10
Number Of Shares Acquired		80,000
Bottom [Member]
Statement [Line Items]
Variablen Interest Rate			4.45%
Top [Member]
Statement [Line Items]
Variablen Interest Rate			4%
Guaranteed Investment Certificate [Member]
Statement [Line Items]
Purchase of notes	$ 744,500		$ 2,985,424
Variablen Interest Rate	2%
Gross proceeds Redeemed amount	$ 738,000
Outstanding balance including interest accrued			3,014,276
Accrued interest			28,852
Guaranteed Investment Certificate [Member] | Bank of Montreal [Member]
Statement [Line Items]
Purchase of notes			$ 500,000
Variablen Interest Rate			4.50%
Outstanding balance including interest accrued			$ 501,171
Accrued interest			$ 1,171

Intangible assets (Details)

Intangible assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Statement [Line Items]
Intangible assets	$ 5,039,901	$ 5,355,687
Accumulated depreciation and amortisation [member]
Statement [Line Items]
Begining balance	958,884	14,225,775
Impairment		(15,361,970)
Ending balance	1,274,670	958,884
Amortization	315,786	2,364,983
Innovet [Member]
Statement [Line Items]
Intangible assets	0	0
Innovet [Member] | Accumulated depreciation and amortisation [member]
Statement [Line Items]
Begining balance	0	229,933
Impairment		(26,266,064)
Ending balance		0
Additions		39,971
Prismic [Member]
Statement [Line Items]
Intangible assets	0	0
Prismic [Member] | Accumulated depreciation and amortisation [member]
Statement [Line Items]
Begining balance	0	13,457,622
Impairment		(15,631,874)
Ending balance		0
Amortization		1,904,348
Lucid [Member]
Statement [Line Items]
Intangible assets	5,039,901	5,355,687
Lucid [Member] | Accumulated depreciation and amortisation [member]
Statement [Line Items]
Begining balance	958,884	538,220
Impairment		0
Ending balance	1,274,670	958,884
Amortization	315,786	420,664
Cost [Member]
Statement [Line Items]
Begining balance	6,314,571	26,266,064
Impairment		(19,951,493)
Ending balance		6,314,571
Cost [Member] | Innovet [Member]
Statement [Line Items]
Begining balance	0	750,000
Impairment		(750,000)
Ending balance		0
Cost [Member] | Prismic [Member]
Statement [Line Items]
Begining balance	0	19,201,493
Impairment		(19,201,493)
Ending balance		0
Cost [Member] | Lucid [Member]
Statement [Line Items]
Begining balance	$ 6,314,571	6,314,571
Impairment		0
Ending balance		$ 6,314,571

Trade and other payables (Detai

Trade and other payables (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Trade and other payables
Trade payables	$ 1,349,552	$ 3,240,658
Accrued liabilities	1,958,384	954,371
Trade and other payables	$ 3,307,936	$ 4,195,029

Trade and other payables (Det_2

Trade and other payables (Details 1) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Trade and other payables
Operational expenses	$ 1,343,340	$ 71,953
Professional and other fees	205,851	473,225
Accrued interest	409,193	409,193
Accrued liabilities	$ 1,958,384	$ 954,371

Warrants Liability (Details)

Warrants Liability (Details) - Warranty Liability [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Statement [Line Items]
Share Price	$ 4	$ 59.80
Exercise price	$ 276.90	$ 276.90
Risk free interest rate	2.94%	3.91%
Expected life (years)	25 days	1 year 7 months 6 days
Expected volatility	136%	66%
Expected dividend yield	0%	0%

Warrants Liability (Details Nar

Warrants Liability (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Statement [Line Items]
Warrants Liability		$ 75		$ 31,338
Warranty Liability [Member]
Statement [Line Items]
Issuance of common stock of direct offering	42,499
Issuance of warrants of direct offering	21,250
Proceeds from direct offering	$ 9,999,997
Exercise price of warrants issued	$ 276.90
Warrants Liability		75		$ 31,338
Gain on change in fair value		$ 31,263	$ 113,211

Notes payable (Details Narrativ

Notes payable (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Statement [Line Items]
Total notes payable balance	$ 300,549	$ 300,549
RH Capital Finance CO LLC [Member]
Statement [Line Items]
Remaining note payable balance	300,549
Issued of note payable	$ 290,387
Interest rate	16%
Accrued interest	$ 30,547

Share capital (Details)

Share capital (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement [Line Items]
Balance, amount	$ 12,909,262	$ 30,542,220
Shares issued amount	1,983,728	0
Balance, amount	15,345,767	14,746,529
Warrants issued, amount		$ 1,330,043
Warrants cancelled , amount	$ 0
Share options exercised shares	248,160	323
Share options exercised amount		$ 20,247
Shares for debt, amount	$ 1,983,728
Class B Common Shares [Member]
Statement [Line Items]
Begininig balance shares	605,796	592,372
Balance, amount	$ 137,626,863	$ 143,258,972
Shares issued amount	9,185,073
Warrants expired amount	$ 0	0
Shares based payment amount		$ 16,000
Ending balance shares	1,864,154	605,520
Balance, amount	$ 148,929,236	$ 137,606,863
Warrants expired shares		0
Warrants cancelled , amount	$ 0
RSU converted to amount shares	7,500
RSU converted to amount	$ 31,009
Shares based payment shares		280
Shares Repurchase shares		(29,303)
Shares Repurchase amount		$ (7,165,356)
Share options exercised shares	1,446	323
Share options exercised amount	$ 102,563	$ 33,247
Shares issued shares	956,935
Shares for debt, share	292,477
Shares for debt, amount	$ 1,983,728
PSU converted to shares		41,848
PSU converted to amount		$ 1,464,000
Class A Common Shares [Member]
Statement [Line Items]
Begininig balance shares	2	2
Balance, amount	$ 151,622	$ 151,588
Shares issued shares	10
Shares issued amount	$ 79
Warrants expired amount	$ 0	0
Shares Repurchase		0
Shares based payment amount		0
Share cancellation amount		$ 0
Ending balance shares	12	2
Balance, amount	$ 151,701	$ 151,588
Warrants issued, amount	0
Warrants expired shares		0
Warrants cancelled , amount	$ 0
RSU converted to amount shares	0	0
RSU converted to amount	$ 0
Represents information of warrant. [Member]
Statement [Line Items]
Begininig balance shares	158,831	99,725
Balance, amount	$ 2,723,356	$ 2,142,400
Shares issued amount	0
Warrants expired amount	$ (286,189)	(791,807)
Shares Repurchase		0
Shares based payment amount		$ 0
Ending balance shares	1,997,759	158,832
Balance, amount	$ 130,370	$ 2,680,636
Warrants issued, amount		$ 1,330,043
Warrants expired shares	(20,769)	(2,047)
Warrants cancelled , amount	$ (439,408)
RSU converted to amount shares	0	0
RSU converted to amount	$ 0
Share options exercised amount	0	$ 0
Shares for debt, amount	$ 0
Warrants issued, share		61,154
Warrants cancelled , share	(7,692)

Share capital (Details 1)

Share capital (Details 1) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Share capital
Begining balance shares	158,831	99,725
Issued	(7,692)	61,154
Expired	20,769	2,047
Ending balance	130,370	158,832
Weighted average exercise Price warrants Outstanding	$ 328.30	$ 356.20
Cancelled	97.50	295.75
Expired	232.19	260.65
Weighted average exercise Price warrants Outstanding	$ 399.64	$ 333.45

Share capital (Details 2)

Share capital (Details 2)	9 Months Ended
	Sep. 30, 2023 $ / shares
Statement [Line Items]
Expected dividend yield	0%
Bottom of the range [member]
Statement [Line Items]
Grant date share price	$ 93.60
Exercise price	$ 97.50
Risk free interest rate	3.08%
Expected life	9 months
Expected volatility	64%
Top of the range [member]
Statement [Line Items]
Grant date share price	$ 148.85
Exercise price	$ 703.30
Risk free interest rate	4.26%
Expected life	5 years
Expected volatility	109%

Share capital (Details 3)

Share capital (Details 3)	Sep. 30, 2024 $ / shares shares
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 399.64
Number of warrants Outstanding | shares	130,370
Warrants by expiry date at May 31st 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 1,737.65
Number of warrants Outstanding | shares	29
Warrants by expiry date at May 15th One 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 195
Number of warrants Outstanding | shares	577
Warrants by expiry date at May 17th, 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 1,737.65
Number of warrants Outstanding | shares	57
Warrants by expiry date at January 16th 2026. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 1,737.65
Number of warrants Outstanding | shares	26
Warrants by expiry date at January 20th 2026. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 1,737.65
Number of warrants Outstanding | shares	6
Warrants by expiry date at August 6th, 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 503.56
Number of warrants Outstanding | shares	21,249
Warrants By Expiry Date At February 27Th 2025 [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 155.69
Number of warrants Outstanding | shares	6,154
Warrants By Expiry Date At February 27 Th 2025 One [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 355.87
Number of warrants Outstanding | shares	6,154
Warrants By Expiry Date At February 27 Th 2025 Two [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 711.74
Number of warrants Outstanding | shares	3,077
Warrants By Expiry Date At May15 Th2025 [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 97.50
Number of warrants Outstanding | shares	577
Warrants by expiry date at May 23RD, 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 97.50
Number of warrants Outstanding | shares	769
Warrants By Expiry Date At March 24Th 2025 [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 155.69
Number of warrants Outstanding | shares	6,154
Warrants By Expiry Date At March 24 Th 2025 One [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 355.87
Number of warrants Outstanding | shares	6,154
Warrants By Expiry Date At March 24 Th 2025 Two [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 711.74
Number of warrants Outstanding | shares	3,077
Warrants by expiry date at October 20th, 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 294.48
Number of warrants Outstanding | shares	53,147
Warrants by expiry date at June 8th 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 627.25
Number of warrants Outstanding | shares	23,077
Warrants by expiry date at May 10th 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 1,737.65
Number of warrants Outstanding | shares	29
Warrants by expiry date at May 4th 2025. [Member]
Statement [Line Items]
Exercise Price warrants Outstanding | $ / shares	$ 1,737.65
Number of warrants Outstanding | shares	57

Share capital (Details Narrativ

Share capital (Details Narrative) - USD ($)		1 Months Ended			2 Months Ended	3 Months Ended	9 Months Ended
	Sep. 06, 2024	Jul. 31, 2024	Jun. 30, 2024	Feb. 29, 2024	Aug. 31, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023
Statement [Line Items]
Aggregate offering price		$ 24,866
Fair Value Of Shares	$ 31,009		$ 109,614
Issuing Shares granted	7,500	2,173					956,935
Share options exercised during period							1,446
Warrants cancelled	7,692
Warrants, exercise price	$ 97.50
Cash commission							$ 288,373
Price per share	$ 4.13	$ 11.44
Transaction fees							9,612,409
Proceeds from issuance of shares							$ 9,185,073
Share options exercised shares							248,160	323
Warrant Share issued for services								61,154
Deemed price							$ 4.02
fair value of warrants							$ 996,705	$ 1,384,969
Expense								1,330,043
Remaining amount of warrants								$ 54,926
Exercise price							$ 71.50	$ 84.50
Other trading expense							$ 138,963
Total share issuance costs							427,336
Settelment amount						$ 524,324	997,920
Loss on settlement of debt							$ 17,476
Warrants expired unexercised							20,769	2,047
Class B Common Stock [Member]
Statement [Line Items]
Share repurchased and canceled								$ 29,303
Converted shares								41,848
Common share exchange option								323
Aggregate offering price		$ 33,057			$ 244,049		$ 11,154,232
Fair Value Of Shares			$ 109,614
Fair Value							$ 541,800
Issuing Shares granted	7,500
Issuing Shares		2,308	7,692	605	22,308	9,231
Warrants, exercise price							$ 97.50
Price per share		$ 14.32	$ 14.25			$ 58.70
Shares based payment amount								$ 16,000
Share issued conversion of RSU							846
Shares based payment shares								280
Deemed price per share				$ 55.90
Share options exercised shares							1,446
Settelment amount		$ 12,321		$ 33,636
Bottom of the range [member]
Statement [Line Items]
Price per share					$ 4.71
Top of the range [member]
Statement [Line Items]
Price per share					$ 14.32

Share based compensation (Detai

Share based compensation (Details) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares	Sep. 30, 2023 $ / shares shares
Statement [Line Items]
Option outstanding, Opening Balance | shares	37,856	6,439
Granted	54,308	38,277
Cancelled	(47,358)	(1,900)
Exercised	(1,446)	(323)
Expired	(904)	(3,516)
Option outstanding, Closing Balance | shares	42,456	38,977
Exercisable	34,123	37,546
Weighted average exercise price, opening balance	$ 101.59	$ 241.15
Weighted average exercise price, Granted	26.24	98.80
Weighted average exercise price, Cancelled	95.84	135.85
Weighted average exercise price, Exercised	97.50	84.50
Weighted average exercise price, Expired	352.83	303.55
Weighted average exercise price, Closing balance	6.97	102.70
Weighted average exercise price, Exercisable	$ 7.30	$ 100.10

Share based compensation (Det_2

Share based compensation (Details 1) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement [Line Items]
Exercise price	$ 71.50	$ 84.50
Stock Options Top [Member]
Statement [Line Items]
Grant date share price	$ 72.15	$ 161.20
Expected life	2 years	5 years
Exercise price	$ 97.50	$ 159.25
Risk free interest rate	4.20%	3.99%
Expected volatility	103%	110%
Stock Options Bottom [Member]
Statement [Line Items]
Grant date share price	$ 2.84	$ 83.20
Expected life		2 years 10 months 28 days
Exercise price	$ 5.25	$ 84.50
Risk free interest rate	2.91%	2.88%
Expected volatility	66%	95%

Share based compensation (Det_3

Share based compensation (Details 2) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Exercise price 154.39 [Member]
Statement [Line Items]
Exercise price of options outstanding	$ 154.39
Number of share options outstanding | shares	228
Weighted average remaining contractual life of outstanding share options	1 year 4 months 28 days
Exercise price of exercisable Share options	$ 154.39
Number of share options exercisable in share-based payment arrangement	228
Exercise price 2.25 [Member]
Statement [Line Items]
Exercise price of options outstanding	$ 5.25
Number of share options outstanding | shares	29,500
Weighted average remaining contractual life of outstanding share options	1 year 11 months 26 days
Exercise price of exercisable Share options	$ 5.25
Number of share options exercisable in share-based payment arrangement	29,500
Exercise price 6.97 [Member]
Statement [Line Items]
Exercise price of options outstanding	$ 6.97
Number of share options outstanding | shares	42,456
Weighted average remaining contractual life of outstanding share options	1 year 11 months 19 days
Exercise price of exercisable Share options	$ 7.30
Number of share options exercisable in share-based payment arrangement	34,123
Exercise price 156.55 [Member]
Statement [Line Items]
Exercise price of options outstanding	$ 156.55
Number of share options outstanding | shares	228
Weighted average remaining contractual life of outstanding share options	1 year 5 months 23 days
Exercise price of exercisable Share options	$ 156.55
Number of share options exercisable in share-based payment arrangement	228
Exercise price 5.60 [Member]
Statement [Line Items]
Exercise price of options outstanding	$ 5.60
Number of share options outstanding | shares	12,500
Weighted average remaining contractual life of outstanding share options	1 year 11 months 4 days
Exercise price of exercisable Share options	$ 5.60
Number of share options exercisable in share-based payment arrangement	4,167

Share based compensation (Det_4

Share based compensation (Details 3)	9 Months Ended
	Sep. 30, 2024 shares
Sharebased compensation
Opening Balance	0
Granted	41,036
Converted to common shares	(8,346)
Closing Balance	32,690

Share based compensation (Det_5

Share based compensation (Details 4) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Statement [Line Items]
Share-based compensation expenses	$ 65,424	$ 126,163	$ 234,691	$ 3,736,091
Performance Share [Member]
Statement [Line Items]
Share-based compensation expenses	0	0	0	458,253
Stock Option [Member]
Statement [Line Items]
Share-based compensation expenses	31,547	5,797	200,814	1,925,492
Other [Member]
Statement [Line Items]
Share-based compensation expenses	0	6,303	0	6,303
Shares For Services [Member]
Statement [Line Items]
Share-based compensation expenses	0	16,000	0	16,000
RSUs [Member]
Statement [Line Items]
Share-based compensation expenses	33,877	0	33,877	0
Warrants Issued For Services [Member]
Statement [Line Items]
Share-based compensation expenses	$ 0	$ 98,063	$ 0	$ 1,330,043

Share-based compensation (Detai

Share-based compensation (Details Narrative)				9 Months Ended
	Sep. 06, 2024 USD ($) shares	Aug. 23, 2024 USD ($)	Feb. 23, 2024 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023
RSUs [Member]
Statement [Line Items]
Shares Granted	7,500	32,690	846
RSUs issued	7,500		846
Fair value of shares issued | $	$ 31,009	$ 137,625	$ 49,665
Share-based compensation expense and contributed surplus | $				$ 2,868
Consultants [Member]
Statement [Line Items]
Shares Granted				12,308
Driector [Member]
Statement [Line Items]
Shares Granted				42,000
Exercise price Minimum | $ / shares				$ 5.25
Exercise price Maximum | $ / shares				$ 5.69
Former Officers And Employees [Member]
Statement [Line Items]
Shares Granted				33,368	3,516
Directors, officers, employees and consultants [Member]
Statement [Line Items]
Number of share cancelled				47,358
Prismic Pharmaceuticals Inc. [Member]
Statement [Line Items]
Shares Granted				54,308	38,277
PSUs Converted to Class B Shares				41,848

Noncontrolling interests (Detai

Noncontrolling interests (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Non-controlling interests
Begining balance	$ (327,501)
Net loss for the period	(616,790)
Ending balance	$ (944,291)

Noncontrolling interests (Det_2

Noncontrolling interests (Details Narrative) - Celly Nutrition Corp. [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Jul. 31, 2023
Statement [Line Items]
Acquisition Percentage			34.66%
Ownership percentage	24.15%	26.15%

Loss per share (Details)

Loss per share (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement [Line Items]
Dilutive effect of convertible instruments on number of ordinary shares	205,516	197,808
RSUs [Member]
Statement [Line Items]
Dilutive effect of convertible instruments on number of ordinary shares	32,690	0
Represents information of warrant. [Member]
Statement [Line Items]
Dilutive effect of convertible instruments on number of ordinary shares	130,370	158,831
Stock Options [Member]
Statement [Line Items]
Dilutive effect of convertible instruments on number of ordinary shares	42,456	38,977

General and administrative (Det

General and administrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
General and administrative
Professional fees	$ 618,906	$ 977,628	$ 2,435,706	$ 2,386,402
Investor relations	543,327	248,206	1,376,543	595,756
Salaries, wages and benefits	1,409,817	352,256	2,225,956	1,448,182
Consulting fees	281,326	247,542	704,779	1,073,413
Office and general administrative	288,702	734,146	638,731	2,047,564
Foreign exchange loss (gain)	107,952	512,111	97,810	108,107
General and administrative	$ 3,250,030	$ 3,071,889	$ 7,479,525	$ 7,659,424

Segment information (Details)

Segment information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Statement [Line Items]
Current assets	$ 13,843,692		$ 13,843,692		$ 11,085,305
Interest expense (income)			397,939
Total operating expenses	4,181,070	$ 3,311,877	9,895,032	$ 21,988,372
Net (loss) income	(4,015,327)	(1,131,200)	(9,459,251)	(16,579,022)
Biopharmaceutical [Member]
Statement [Line Items]
Current assets	6,860,179		6,860,179		3,897,317
Non-current assets	5,183,110		5,183,110		5,482,157
Current liabilities	3,681,035		3,681,035		4,565,566
Non-current liabilities	0		0		0
Interest expense (income)	(14,107)	(22,545)	(1,998)	(193,848)
Total operating expenses	4,181,008	3,311,874	9,894,725	21,988,188
Net (loss) income	(4,165,026)	(1,951,904)	(9,897,762)	(17,017,562)
Strategic Investment [Member]
Statement [Line Items]
Current assets	6,983,513		6,983,513		7,187,988
Non-current assets	0		0		907,366
Current liabilities	0		0		0
Non-current liabilities	0		0		0
Interest expense (income)	(149,761)	(151,523)	(438,818)	(438,724)
Total operating expenses	62	3	307	184
Net (loss) income	149,699	820,704	438,511	438,540
Total Consolidated [Member]
Statement [Line Items]
Current assets	13,843,692		13,843,692		11,085,305
Non-current assets	5,183,110		5,183,110		6,389,523
Current liabilities	3,681,035		3,681,035		4,565,566
Non-current liabilities	0		0		$ 0
Interest expense (income)	(163,868)	(174,068)	(440,816)	(632,572)
Total operating expenses	4,181,070	3,311,877	9,895,032	21,988,372
Net (loss) income	$ (4,015,327)	$ (1,131,200)	$ (9,459,251)	$ (16,579,022)

Commitments and contingencies (

Commitments and contingencies (Details Narrative)		1 Months Ended		9 Months Ended
	Feb. 06, 2023 USD ($)	Jun. 27, 2024	Sep. 28, 2023 CAD ($)	Sep. 30, 2024 CAD ($)	Sep. 30, 2024 USD ($)
Raza Bokhari [Member]
Statement [Line Items]
Severance And Damages Amount					$ 30,200,000
Legal expenses			$ 165,000
Description of granted judgement		the US District Court for the Eastern District of Pennsylvania confirmed Quantum’s motion for entry of judgment and granted judgment in favor of Quantum of approximately USD 3 million
Awarded additional costs in light by court	$ 5,000
GBB Drink Lab, Inc [Member]
Statement [Line Items]
Description related to court dispute				GBB Drink Lab, Inc. (“GBB”) has filed a complaint with the United States District Court of Southern District of Florida, Fort Lauderdale Division against FSD Biosciences, Inc. and Quantum, claiming a material breach of a mutual non-disclosure agreement and misappropriation of trade secrets, which GBB claims has and continues to cause irreparable harm, valued, as of August 30, 2022 (prior to the misappropriation and material breach) at $53,047,000	GBB Drink Lab, Inc. (“GBB”) has filed a complaint with the United States District Court of Southern District of Florida, Fort Lauderdale Division against FSD Biosciences, Inc. and Quantum, claiming a material breach of a mutual non-disclosure agreement and misappropriation of trade secrets, which GBB claims has and continues to cause irreparable harm, valued, as of August 30, 2022 (prior to the misappropriation and material breach) at $53,047,000
Lucid Ms And Lucid Psych [Member]
Statement [Line Items]
License Maintenance Fee				$ 100,000
Lucid Ms And Lucid Psych Top [Member]
Statement [Line Items]
License Maintenance Fee				$ 12,500,000
CEO [Member]
Statement [Line Items]
Severance And Damages Amount					$ 30,200,000
Punitive Damages Amount					$ 500,000

Related party transactions (Det

Related party transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related party transactions
Salaries, benefits, bonuses and consulting fees	$ 1,217,268	$ 374,667	$ 1,693,796	$ 1,047,111
Share-based payments	21,530	0	2,366,146	1,963,983
Key management personnel compensation	$ 1,238,798	$ 374,667	$ 4,059,942	$ 3,011,094

Related party transactions (D_2

Related party transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Statement [Line Items]
Amount owed to executive officer					$ 140,012
Performance Share Units [Member]
Statement [Line Items]
Performance Share Units Granted			0	6,154
Director [Member]
Statement [Line Items]
Directors remuneration expense	$ 31,294	$ 38,183	$ 131,010	$ 142,528
CEO and COO [Member]
Statement [Line Items]
Performance Share Units Granted			0	7,692
Exercise price					$ 84.50
Proceeed from secured loan agreement			$ 1,200,000
Monthly payments			6,000
Payments			$ 400,000
Annual interest rate			6%
Independent Director [Member]
Statement [Line Items]
Warrants issued for consulting services				1,539
Fair value				$ 533,206

Capital management (Details Nar

Capital management (Details Narrative) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Capital Management
Share Capital	$ 149,080,937	$ 137,778,485

Subsequent events (Details Narr

Subsequent events (Details Narrative) - USD ($) shares in Millions	1 Months Ended
	Oct. 20, 2024	Nov. 05, 2024	Oct. 31, 2024
Subsequent events
Total outstanding debt Settlement amount		$ 278,000	$ 611,000
Seeking damages exceeding	$ 700,000,000
Seeking damages exceeding, shares	90
Settlement Debt			211,000
Reduction in Settlement Debt			$ 400,000